Published online Dec 16, 2017. doi: 10.12998/wjcc.v5.i12.446
Peer-review started: June 15, 2017
First decision: August 7, 2017
Revised: August 11, 2017
Accepted: September 3, 2017
Article in press: September 4, 2017
Published online: December 16, 2017
Processing time: 177 Days and 14.3 Hours
Core tip: Peripheral neuropathy is a rare adverse effect of short- or long-term use of antiepileptic drugs (phenytoin, phenobarbital, carbamazepine, valproate, gabapentin, levetiracetam and lacosamide). This is the first case report of topiramate induced peripheral neuropathy (TIPN). Manifestations of TIPN are distal paresthesia, areflexia, sensory deficits and reduced amplitudes and nerve conduction velocities of motor and sensory peripheral nerves of the lower extremities indicating demyelinating and axonal neuropathies. The risk is greater with long-term therapy. The mechanisms of TIPN may involve impairment of nerve function through blocking of sodium voltage channels, enhancement of gamma amino butyric acid inhibitory neurotransmission or others.
